Jonathan Goldman - Nov 14, 2025 Form 4 Insider Report for Avalo Therapeutics, Inc. (AVTX)

Role
Director
Signature
/s/ Donald R. Reynolds, by Power of Attorney
Stock symbol
AVTX
Transactions as of
Nov 14, 2025
Transactions value $
-$81,921
Form type
4
Date filed
11/17/2025, 04:05 PM
Previous filing
Jun 18, 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Goldman Jonathan Director C/O AVALO THERAPEUTICS, INC., 1500 LIBERTY RIDGE DRIVE, SUITE 321, WAYNE /s/ Donald R. Reynolds, by Power of Attorney 2025-11-17 0002013869

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AVTX Common Stock Sale -$45.3K -3.17K -100% $14.30 0 Nov 14, 2025 Direct
transaction AVTX Common Stock Options Exercise $81K +8.2K $9.88 8.2K Nov 14, 2025 Direct
transaction AVTX Common Stock Sale -$118K -8.2K -100% $14.35 0 Nov 14, 2025 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AVTX Stock Option (Right to Buy) Options Exercise $0 -8.2K -33.33% $0.00 16.4K Nov 14, 2025 Common Stock 8.2K $9.88 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reported securities were sold in multiple transactions at prices ranging from $14.02 to $14.60. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.
F2 The stock option vests 1/3 on March 28, 2025, March 28, 2026 and March 28, 2027, subject to the Eligible Director's continued service on such vesting date.